SCHEMBL2156357

SCHEMBL2156357

O=C1C(=O)c2c3ccccc3cc3cccc1c23.O=C1C(=O)c2c3ccccc3cc3cccc1c23

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CES1 P23141 4/20 1.00
DNMT1 P26358 2/20 0.55
ALDH1A1 P00352 3/20 0.52
CES2 O00748 2/20 0.52
BCHE P06276 2/20 0.52
MCL1 Q07820 1/20 0.52
CASP1 P29466 2/20 0.46
PABPC1 P11940 2/20 0.46
CYP3A4 P08684 1/20 0.46
CASP7 P55210 1/20 0.46
MAOA P21397 4/20 0.44
MAPK1 P28482 2/20 0.44
ERBB2 P04626 1/20 0.44
CYP1A2 P05177 1/20 0.44
FYN P06241 1/20 0.44
ACHE P22303 1/20 0.44
AHR P35869 1/20 0.44
HPGD P15428 1/20 0.44
TSHR P16473 1/20 0.44
HIF1A Q16665 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL579274 1.00 CES1 (1.00) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL8758317 0.92 CES1 (0.84) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL29773016 0.84 CES1 (0.73) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL31619723 0.84 CES1 (0.72) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL8545834 0.82 CES1 (0.69) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL15243604 0.79 CES1 (0.65) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL15243608 0.79 CES1 (0.65) CES1DNMT1ALDH1A1MCL1CASP1
SCHEMBL14257654 0.79 CES1 (0.64) CES1DNMT1ALDH1A1CES2BCHE
SCHEMBL580216 0.79 CES1 (0.65) CES1DNMT1ALDH1A1CASP1MAOA
SCHEMBL29531588 0.79 CES1 (0.65) CES1DNMT1ALDH1A1CASP1PABPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7973034-B2 Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2011-07-05 US disclosed
US-20050054691-A1 Carboxylesterase inhibitors ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) 2005-03-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050054691-A1 Carboxylesterase inhibitors CES1, CES2, BCHE CES1 1/4885DNMT1 3996/4885ALDH1A1 227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.